The lung resistance protein (LRP) predicts poor outcome in acute myeloid leukemia

Advances in Experimental Medicine and Biology

Volumn 457, Issue , 1999, Pages 133-139

  Pirker, Robert ^a   Pohl, Gudrun ^a   Stranzl, Thomas ^a   Suchomel, Ralf W ^a   Scheper, Rik J ^a,b   Jäger, Ulrich ^a   Geissler, Klaus ^a   Lechner, Klaus ^a   Filipits, Martin ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acute myeloid leukemia; Drug resistance; LRP; Lung resistance protein; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DAUNORUBICIN; DAV REGIMEN; ETOPOSIDE; IDARUBICIN; LUNG RESISTANCE PROTEIN; MONOCLONAL ANTIBODY; RETINOIC ACID; RIBONUCLEOPROTEIN; TUMOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KARYOTYPING; MALE; MIDDLE AGED; MORTALITY; MULTIDRUG RESISTANCE; PATHOLOGY; PREDICTION AND FORECASTING; PROGNOSIS; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DAUNORUBICIN; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, MULTIPLE; ETOPOSIDE; FEMALE; HUMANS; IDARUBICIN; IMMUNOHISTOCHEMISTRY; KARYOTYPING; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL RATE; TRETINOIN; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 0032605815     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-4811-9_15     Document Type: Article

References (23)

1. Pastan I, Gottesman M. Multiple-drug resistance in human cancer. N Engl J Med 1987, 316, 1388-1393
2. Filipits M, Suchomel RW, Zöchbauer S, Malayeri R, Pirker R. Clinical relevance of drug resistance genes in malignant diseases. Leukemia 1996, 10 (Suppl. 3), 10-17
3. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV, Deeley RG. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992, 258, 1650-1654
4. Pirker R, Wallner J, Geissler K, Linkesch W, Haas OA, Bettelheim P, Hopfner M, Scherrer R, Valent P, Havelec L, Ludwig H, Lechner K. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 1991, 83, 708-712
5. Marie J-P, Zittoun R, Sikic BI. Multidrug resistance (mdrl) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 1991, 78, 586-592
6. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992, 79, 473-476
7. Zöchbauer S, Gsur A, Brunner R, Kyrle PA, Lechner K, Pirker R. P-glycoprotein expression as unfavorable prognostic factor in acute myeloid leukemia. Leukemia 1994, 8, 974-977
8. Filipits M, Suchomel RW, Zöchbauer S, Brunner R, Lechner K, Pirker R: Multidrug resistance-associated protein (MRP) in acute myeloid leukemia: no impact on treatment outcome. Clin Cancer Res 1997, 3, 1419-1425
9. Filipits M, Stranzl T, Pohl G, Suchomel RW, Zöchbauer S, Brunner R, Lechner K, Pirker R. MRP expression in acute myeloid leukemia: an update. This volume (Chapter 16)
10. Kuss BJ, Deeley RG, Cole SPC, Willman CL, Kopecky KJ, Wolman SR, Eyre HJ, Lane SA, Nancarrow JK, Whitmore SA, Callen DF. Deletion of gene for multidrug resistance in acute myeloid leukaemia with inversion in chromosome 16: prognostic implications. Lancet 1994, 343, 1531-1534
11. M. Zöchbauer S, Haas OA, Schwarzinger I, Lechner K, Pirker R. Multidrug resistance in acute myeloid leukaemia with inversion in chromosome 16 or FAB M4Eo subtype. Lancet 1994, 344, 894
12. r 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 1993, 53, 1475-1479
13. Scheffer GL, Wijngaard PLJ, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJLM, Clevers HC, Scheper RJ. The drug resistance-related protein LRP is the human major vault protein. Nat Med 1995, 1, 578-582
14. Kedersha NL, Miquel M-C, Bittner D, Rome LH. Vaults. II. Ribonucleoprotein structures are highly conserved among higher and lower eukaryotes. J Cell Biol 1990, 110, 895-901
15. Rome L, Kedersha N, Chugani D: Unlocking vaults: organelles in search of a function. Trends Cell Biol 1991, 1, 47-50
16. Izquierdo MA, Shoemaker RH, Flens MJ, Scheffer GL, Wu L, Prather TR, Scheper RJ. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. Int J Cancer 1996, 65, 230-237
17. Izquierdo MA, Scheffer GL, Flens MJ, Giaccone G, Broxterman HJ, Meijer CJLM, van der Valk P, Scheper RJ. Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. Am J Pathol 1996, 148, 877-887
18. Filipits M, Pohl G, Stranzl T, Suchomel RW, Scheper RJ, Jäger U, Geissler K, Lechner K, Pirker R. Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood 1998, 91, 1508-1513
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53, 457-481
20. List AF, Spier CS, Grogan TM, Johnson C, Roe DJ, Greer JP, Wolff SN, Broxterman HJ, Scheffer GL, Scheper RJ, Dalton WS. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 1996, 87, 2464-2469
21. Ghaddar HM, Plunkett W, Kantarjian HM, Pierce S, Freireich EJ, Keating MJ, Estey EH. Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside. Leukemia 1994, 8, 1269-1274
22. Lum BL, Fisher GA, Brophy NA, Yahanda AM, Adler KM, Kaubisch S, Halsey J, Sikic BI. Clinical trials of modulation of multidrug resistance. Cancer 1993, 72, 3502-3514
23. Pirker R, Keilhauer G, Raschack M, Lechner C, Ludwig H. Reversal of multi-drug resistance in human KB cell lines by structural analogs of verapamil. Int J Cancer 1990, 45, 916-919